In regenerative medicine, scientists aim to significantly advance techniques that can control stem cell lineage commitment. For example, mechanical stimulation of mesenchymal stem cells (MSCs) at the nanoscale can activate mechanotransduction pathways to stimulate osteogenesis (bone development) in 2-D and 3-D culture. Such work can revolutionize bone graft procedures by creating graft material from autologous or allogenic sources of MSCs without chemically inducing the phenomenon. Due to increasing biomedical interest in such mechanical stimulation of cells for clinical use, both researchers and clinicians require a scalable bioreactor system to provide consistently reproducible results. In a new study now published on Scientific Reports, Paul Campsie and a team of multidisciplinary researchers at the departments of biomedical engineering, computing, physics, and molecular, cell and systems biology engineered a new bioreactor system to meet the existing requirements.